Tundup I completely agree, as I’ve stated a few times before; great science team mediocre (being kind) management. 

BUT ......I think this does clear the way for the partnership/licensing agreements management has been yapping about for sometime now. When and since the LoC deadline was given its short extension, I have thought that management was dreaming in technicolor if they really believed that a potential partner or licensee would cough up big dollars for a partnership or regional license with a company that was in imminent danger of losing all its IP. Now that the LoC issue will be cleared up we may see a number of companies interested in being involved with leading edge epigenetic IP. If management is even half way competent they should be able to make deals for CKD, Fabry’s and some of the 6 or 7 “clinic ready” compounds we have been hearing about for some time. 

I think one of the things management did well was provide a good road map for EV wrt Cardiovascular and CKD. IMO A few good deals, wrt ALL the IP, and a positive FA announcement should do a lot for placing the market cap somewhere in that chart in the not to distant future. That obviously would be good for our share price despite the dilution. We will see if management is up to the task. JMO